YMRS (Young Mania Rating Scale)
Psychiatry· appears in 22+ cited findings in this library
What it is and how the reviews use it
The YMRS (Young Mania Rating Scale) is an endpoint used in regulatory review documents to assess the severity of manic symptoms. It serves as a measure for evaluating the efficacy of treatments for conditions involving mania, and is utilized in clinical trials to determine patient eligibility and treatment outcomes.
In the provided regulatory reviews, the YMRS is used in various contexts. For instance, it was an exclusion criterion for AbbVie Inc.'s Vraylar, where patients with a YMRS score of ≥ 12 were excluded. Conversely, for Johnson & Johnson's Caplyta, an inclusion criterion was a YMRS total score of <12. Organon & Co.'s Sycrest demonstrated a pooled treatment effect on the YMRS scale of -4.9 points in a meta-analysis.
Real examples — cited to the source page
| Vraylar | Exclusion criteria: YMRS score | ≥ 12 | AbbVie Inc. — Vraylar FDA Review (NDA204370, SUPPL 9, 2022), p.253 |
| Caplyta | Inclusion criteria: YMRS total score | <12 | Johnson & Johnson — Caplyta FDA Review (NDA209500, SUPPL 6, 2021), p.187 |
| Sycrest | Pooled treatment effect on YMRS scale (meta-analysis) | -4.9 | Organon & Co. — Sycrest EMA EPAR public assessment report (EMEA/H/C/00, p.68 |
Different drugs were studied in different trials — these values are not head-to-head comparisons.
Explore the full evidence
Every YMRS finding in the library — searchable and answerable in plain language — is in the Psychiatry research library →
Figures are as stated in the cited source documents. Educational reference only — not medical or investment advice.